These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21107309)

  • 1. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
    McClay JL; Adkins DE; Aberg K; Bukszár J; Khachane AN; Keefe RS; Perkins DO; McEvoy JP; Stroup TS; Vann RE; Beardsley PM; Lieberman JA; Sullivan PF; van den Oord EJ
    Neuropsychopharmacology; 2011 Feb; 36(3):616-26. PubMed ID: 21107309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
    McClay JL; Adkins DE; Aberg K; Stroup S; Perkins DO; Vladimirov VI; Lieberman JA; Sullivan PF; van den Oord EJ
    Mol Psychiatry; 2011 Jan; 16(1):76-85. PubMed ID: 19721433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
    Yu H; Yan H; Wang L; Li J; Tan L; Deng W; Chen Q; Yang G; Zhang F; Lu T; Yang J; Li K; Lv L; Tan Q; Zhang H; Xiao X; Li M; Ma X; Yang F; Li L; Wang C; Li T; Zhang D; Yue W;
    Lancet Psychiatry; 2018 Apr; 5(4):327-338. PubMed ID: 29503163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.
    Clark SL; Souza RP; Adkins DE; Aberg K; Bukszár J; McClay JL; Sullivan PF; van den Oord EJ
    Pharmacogenet Genomics; 2013 Feb; 23(2):69-77. PubMed ID: 23241943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.
    Adkins DE; Aberg K; McClay JL; Bukszár J; Zhao Z; Jia P; Stroup TS; Perkins D; McEvoy JP; Lieberman JA; Sullivan PF; van den Oord EJ
    Mol Psychiatry; 2011 Mar; 16(3):321-32. PubMed ID: 20195266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
    Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
    Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.
    Ramsey TL; Liu Q; Massey BW; Brennan MD
    Schizophr Res; 2013 Sep; 149(1-3):21-5. PubMed ID: 23886675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
    Ramsey TL; Brennan MD
    Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
    Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
    Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
    Sacchetti E; Magri C; Minelli A; Valsecchi P; Traversa M; Calza S; Vita A; Gennarelli M
    Pharmacogenomics J; 2017 Mar; 17(2):146-154. PubMed ID: 26856250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common genetic variation and schizophrenia polygenic risk influence neurocognitive performance in young adulthood.
    Hatzimanolis A; Bhatnagar P; Moes A; Wang R; Roussos P; Bitsios P; Stefanis CN; Pulver AE; Arking DE; Smyrnis N; Stefanis NC; Avramopoulos D
    Am J Med Genet B Neuropsychiatr Genet; 2015 Jul; 168B(5):392-401. PubMed ID: 25963331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
    van Veelen NM; Grootens KP; Peuskens J; Sabbe BG; Salden ME; Verkes RJ; Kahn RS; Sitskoorn MM
    Schizophr Res; 2010 Jul; 120(1-3):191-8. PubMed ID: 20493663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
    Meltzer HY; McGurk SR
    Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT1 and neurocognition in schizophrenia.
    Pinheiro AP; Keefe RS; Skelly T; Olarte M; Leviel K; Lange LA; Lange EM; Stroup TS; Lieberman J; Sullivan PF
    Aust N Z J Psychiatry; 2007 Feb; 41(2):169-77. PubMed ID: 17464696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics.
    Schuhmacher A; Becker T; Rujescu D; Quednow BB; Lennertz L; Wagner M; Benninghoff J; Rietschel M; Häfner H; Franke P; Wölwer W; Gaebel W; Maier W; Mössner R
    J Psychiatr Res; 2012 Aug; 46(8):1073-80. PubMed ID: 22655589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.